In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27

Cancer Biology and Therapy

Volumn 4, Issue 7, 2005, Pages 763-768

  Abbas Rizvi, Syed M ^a   Chang, Fa Qu ^a,b   Yan, Jun Song ^a,b   Raja, Chand ^b   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alpha immunoconjugate; Intralesional and systemic TAT; Monoclonal antibody 9.2.27; Pharmacokinetics and biodistribution; Single and multiple efficacy dose regimens; Targeted alpha therapy; Tumor metastases

Indexed keywords

BISMUTH 213; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9.2.27; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LIVER; MOUSE; NONHUMAN; TUMOR GROWTH;

EID: 25144488625     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.7.1868     Document Type: Article

References (44)

1. Herlyn M. Human melanoma: Development and Progression. Cancer Metastasis Rev 1990; 9:101-12.
2. Liotta LA, Steeg PS, Steler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64:327-36.
3. Rusciano D, Burger MM. Mechanisms of metastasis. In: Levine AJ, Schmidek HH, eds. Molecular Genetics of Nervous System Tumours. New York: Wiley-Liss Inc., 1993:357-69.
4. Vile RG. The metastatic cascade. In: Vile RG, ed. Cancer Metastasis: From Mechanisms to Therapies. London (UK): Imperial Cancer Research Fund, 1995:1-20.
5. Jones VE, Mitchell MS. Therapeutic vaccines for melanoma: Progress and problems. TIBTECH 1996; 14:349-55.
6. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991; 10:115-28.
7. Mortarini R, Anchini A. From adhesion to signaling: Roles of integrins in the biology of human melanoma. Melanoma Res 1993; 3:87-97.
8. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumour growth and metastasis. Cancer Res 1997; 57:2295-303.
9. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991; 51:6660-7.
10. van Mujan G, Danen E, Veerkamp J, Ruiter D, Leslie J, van den Heuvel L. Glycoconjugate profile and CD44expression in human melanoma cell lines with different metastatic capacity. Int J Cancer 1994; 61:41-8.
11. Harper JR, Reisfeld RA. Cell-associated proteoglycans in human malignant melanoma. In: Wight T, Mecham R, eds. Biology of Proteoglycans. Orlando, Florida (USA): Academic Press Inc., 1987:345-66.
12. Kramer RH, Vu M, Cheng Y-F, Ramos DM. Integrin expression in malignant melanoma. Cancer Metastasis Rev 1991; 10:49-59.
13. Edward M. Integrins and other adhesive molecules involved in melanocytic tumour progression. Curr Opin Oncol 1995; 7:185-191.
14. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovick L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumour progression. Cancer Res 1990; 50:6757-64.
15. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992; 10:111-20.
16. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens for melanocytes and melanoma: Markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982; 156:1755-66.
17. Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985; 45:4401-11.
18. Takahashi HS, Oettgen HF, Old LJ. Cell surface antigen of human malignant melanoma II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 1976; 144:873-81.
19. Lewis MG. Separation of two distinct tumour-associated antibodies in serum of melanoma patients. J Natl Cancer Inst 1972; 49:915-7.
20. Woodbury RG, Brown JP, Yeh M-Y, Hellstrom I, Hellstrom KE. Identification of cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci USA 1980; 77:2183-7.
21. Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 1978; 75:3405-3409.
22. Liao SK, Kwong PC, Thompson JC, Dent PB. Spectrum of melanoma antigens on cultured human melanoma cells as detected by monkey antibodies. Cancer Res 1979; 39:183-92.
23. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 1982; 79:1245-9.
24. Morgan AC, Galloway DR, Reisfeld RA. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1982; 1:27-33.
25. Nishiyama A, Lin X-H, Giese N, Heldin C-H, Stallcup WB. Colocalization of NG2 proteoglycan and PDGF α receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res 1996; 43:299-314.
26. Nishiyama A, Lin X-H, Giese N, Heldin C-H, Stallcup WB. Interaction between NG2 proteoglycan and PDGF α receptor is required for optimal response to PDGF. J Neurosci Res 1996; 43:315-30.
27. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA. Molecular cloning of a human melanoma-associated chndroitin sulfate proteoglycan. Proc Natl Acad Sci USA 1996; 93:9710-5.
28. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 1998; 177:299-312.
29. Bumol TF, Wang QC, Reisfeld RA, Kaplan NO. Monoclonal antibody and an antibody-toxin conjugate to a cell-surface proteoglycan of melanoma cells suppress in vivo tumour growth. Proc Natl Acad Sci USA 1983; 80:529-33.
30. Schrappe M, Bumol TF, Apelgren LD, Briggs SL, Koppel GA, Markowitz DD, Mueller BM, Reisfeld RA. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-Desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 1992; 52:3838-44.
31. Allen BJ. Targeted alpha therapy: Evidence for efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 1999; 43:480-6.
32. Allen BJ, Rizvi SMA, Li Y, Tian Z, Ranson M. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Critical Rev Oncol/Haem 2001; 3:139-46.
33. Allen BJ, Blagojevic N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149. Nucl Med Commun 1996; 17:40-7.
34. Lloyd EL, Gemmell MA, Henning CB, Gemmell DS, Zabransky BJ. Cell survival following multiple-track alpha particle irradiation. Int J Rad Biol & Related Studies in Physics, Chemistry & Medicine 1979; 35:23-31.
35. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiation Res 1986; 105:27-36.
36. Rizvi SMA, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 2000; 10:281-90.
37. Allen BJ, Rizvi SMA, Tian Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res 2000; 11:175-82.
38. Dawson MRL, Levine JM, Reynolds R. NG2-expressing cells in central nervous system: Are they oligodendroglial progenitors? J Neurosci Res 2000; 61:471-9.
39. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095-100.
40. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitter therapy of micrometastases: 213Bi-J591 (anti-PSMA) treatment of LNCaP spheroids. Proc Am Assoc Cancer Res 1998; 39:440.
41. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999; 40:166-76.
42. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting radionuclides. Eur J Nucl Med 1998; 25:1341-51.
43. McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA. Preparation of alpha-emitting bismuth-213 labeled antibody constructs for clinical use. J Nucl Med 1999; 40:1722-7.
44. Schmidt D, Neumann F, Antke C, Apostilidis C, Martin S, Morgenstern A, et al. Phase 1 clinical study on alpha-therapy for Non Hodgkin's Lymphoma. Proceedings of the 4 th Alpha Immunotherapy Symposium 2004:12.